Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240472 | 1.00 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL2877547 | 0.89 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL27240680 | 0.89 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL26697717 | 0.89 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL24186458 | 0.83 | USP30 (0.38) | MAPK1P2RX7 | |
| SCHEMBL20442937 | 0.83 | USP30 (0.38) | MAPK1P2RX7 | |
| SCHEMBL21326425 | 0.83 | USP30 (0.38) | MAPK1P2RX7 | |
| SCHEMBL275602 | 0.75 | MAPK1 (0.37) | MAPK1P2RX7 | |
| SCHEMBL27240314 | 0.74 | MAPK1 (0.39) | MAPK1P2RX7 | |
| SCHEMBL27240308 | 0.74 | MAPK1 (0.39) | MAPK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190868-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | MAPK1 68/4885P2RX7 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.